A Phase II, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine
Latest Information Update: 30 Mar 2011
At a glance
- Drugs Talmapimod (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SPRiNG
- 15 Oct 2010 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2008 Results were presented at the American College of Rheumatology meeting in Oct 2008. Endpoints added. Actual patient numbers added. Link to ADNM 801127187 added.